Michael Reed et al. JCIN 2009;2:

Slides:

Advertisements

Similar presentations

A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.

Advertisements

Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.

REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced.

Contrast Induced Nephropathy: Predictors, Prevention, and Management Columbia University Medical Center Cardiovascular Research Foundation Roxana Mehran,

臨床藥事照護年 09 月其他之用藥建議疑問藥物問題內容後續追蹤 Actein qid 2 包非正常使用 dose FOR CKD 病人的腎臟保護 2 文獻資料資料來源 Prophylactic oral administration of the antioxidant.

Radiocontrast Nephropathy Jason S. Finkelstein, M.D. Tulane University HSC Division of Cardiology 3/2/04.

CARE Cardiac Angiography in REnally impaired patients: A comparison between Iodixanol (Visipaque) and Iopamidol (Isovue) in high risk patients for contrast.

Hexabrix Key Clinical Review Liss, 2006 Mid-Year Sales Meeting Bloomington, IN July 13 th – 17 th.

Flow diagram of the systematic literature search indicating the inclusion and exclusion process of studies Liakopoulos OJ, et al. Eur Heart J 2008;29:

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Obstructive Sleep Apnea Treatment on Atrial.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prognostic Value of Cardiac Computed Tomography.

1 CONTRAST - INDUCED ACUTE RENAL INJURY. Acute Renal Failure Nephrotoxic ATN Endogenous Toxins –Heme pigments (myoglobin, hemoglobin) –Myeloma light chains.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:

The SPRINT Research Group

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Zhi-hui Hou et al. JIMG 2012;5:

Hexabrix Key Clinical Review Mehran, 2009

Contrast-Induced Acute Kidney Injury: Specialty-Specific Protocols for Interventional Radiology, Diagnostic Computed Tomography Radiology, and Interventional.

Waddah Maskoun et al. JACEP 2016;2:

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Shadi Al Halabi et al. JACEP 2015;1:

Dean J. Kereiakes et al. JACC 2017;70:

chemotherapy for patients with MC versus those with AC

Ashish Shukla et al. JACEP 2015;1:41-51

Dileep Raman et al. JACEP 2017;3:

Section 4: Contrast-induced AKI

Pablo B. Nery et al. JACEP 2016;2:

Wesley T. O’Neal et al. JACEP 2016;2:

AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.

Hexabrix Key Clinical Review Le Feuvre, 2006

Prehypertension and Incidence of ESRD: A Systematic Review and Meta-analysis Yuli Huang, MD, Xiaoyan Cai, MD, Jianyu Zhang, MD, Weiyi Mai, MD, PhD, Sheng.

Gregory Piazza et al. JCIN 2015;8:

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Miralem Pasic et al. JCIN 2015;8:1-9

Volume 68, Issue 5, Pages (November 2005)

John A. Bittl et al. JACC 2016;68:

Ashraf Hamdan et al. JCIN 2015;8:

Yousef Rezaei, MD American Journal of Kidney Diseases

Mintu P. Turakhia et al. JACEP 2016;2:

Svend A. Mortensen et al. JCHF 2014;2:

S.M. Afzal Sohaib et al. JACEP 2015;1:

Prabhat Kumar et al. JACEP 2016;j.jacep

Marwan Badri et al. JACEP 2015;1:

Renal Replacement Therapy in Acute Kidney Injury

Toshiaki Toyota et al. JCIN 2017;10:27-37

P. Michael Grossman et al. JCIN 2009;2:

Noboru Ichihara et al. JACEP 2016;2:

Yusuke Watanabe et al. JCIN 2016;9:

Dennis G. Moledina, MD, Mark A. Perazella, MD

Volume 77, Issue 8, Pages (April 2010)

Volume 73, Issue 5, Pages (March 2008)

Giuseppe Gargiulo et al. JACC 2018;71:

Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.

Davide Capodanno et al. JCIN 2009;2:

Herbert D. Aronow et al. JCIN 2015;8:49-56

Section 4: Contrast-induced AKI

Saadia Sherazi et al. JACEP 2015;1:74-80

Leslee J. Shaw et al. JIMG 2010;3:

Ryan R. Reeves et al. JCIN 2015;8:

Kidney Injury after Intravenous versus Intra-arterial Contrast Agent in Patients Suspected of Having Coronary Artery Disease: A Randomized Trial Acute.

Christian Madelaire et al. JCHF 2018;6:

Gregory Piazza et al. JCIN 2015;8:

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.

Gianluigi Savarese et al. JCHF 2016;4:

Miralem Pasic et al. JCIN 2015;8:1-9

Presentation transcript:

Michael Reed et al. JCIN 2009;2:645-654 Forest Plot of RR of CI-AKI Forest plot of risk ratios (RR) of contrast-induced acute kidney injury (CI-AKI) of pooled trials. Total number of patients in iodixanol group = 1,291. Total number of patients in the low-osmolar contrast media (LOCM) group = 1,289. ACTIVE = Abdominal Computed Tomography: IOMERON 400 versus VISIPAQUE 320 Enhancement Study; CARE = Cardiac Angiography in Renally Impaired Patients Study; CI = confidence interval; ICON = Ionic Versus Nonionic Contrast to Obviate Worsening Nephropathy After Angioplasty in Chronic Renal Failure Patients; IMPACT = renally IMpaired PAtients undergoing Computed Tomography; IX = iodixanol; NEPHRIC = Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study; PREDICT = Patients with Renal Impairment and Diabetes undergoing Computed Tomography; RECOVER = Renal Toxicity Evaluation and Comparison Between Visipaque and Hexabrix in Patients With Renal Insufficiency Undergoing Coronary Angiography; VALOR = Visipaque Angiography/Interventions With Laboratory Outcomes in Renal Insufficiency Study. Michael Reed et al. JCIN 2009;2:645-654 American College of Cardiology Foundation